Literature DB >> 9783238

Comparison of percentage area of myocardial fibrosis and disarray in patients with classical form and dilated phase of hypertrophic cardiomyopathy.

K Iida1, C Yutani, M Imakita, H Ishibashi-Ueda.   

Abstract

This study compared the percentage area of myocardial fibrosis and disarray between hypertrophic cardiomyopathy (HCM) and DHCM (progression to dilatation of the left ventricle in patients with HCM, i.e., dilated phase HCM), and investigated whether DHCM is included in the natural course of HCM. Twenty-six autopsied hearts were studied, 14 from patients with HCM, and 12 from patients with DHCM, classified by age/decade group. The section at the level of the binding site of papillary muscle was used for the morphometrical examination. In the overall evaluation of both ventricles, all 4 HCM age groups showed percentage area of myocardial fibrosis < 10%, and the value gradually increased with age. In contrast, the percentage area of the DHCM cases was over 20%, and these cases showed diffuse massive fibrosis that did not increase with age. The percentage area of myocardial disarray was over 90% in 3 cases with DHCM. The percentage areas of myocardial fibrosis and disarray of the DHCM hearts were extremely high compared with the HCM hearts, indicating that DHCM is not included in natural course of HCM. Other abnormalities including contractile proteins may be important role in the widespread myocardial disarray leading to massive fibrosis in the pathogenesis of DHCM.

Entities:  

Mesh:

Year:  1998        PMID: 9783238

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  1 in total

1.  Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with MYL2-R58Q-Mediated Apical Hypertrophic Cardiomyopathy Show Hypertrophy, Myofibrillar Disarray, and Calcium Perturbations.

Authors:  Wei Zhou; J Martijn Bos; Dan Ye; David J Tester; Sybil Hrstka; Joseph J Maleszewski; Steve R Ommen; Rick A Nishimura; Hartzell V Schaff; Chang Sung Kim; Michael J Ackerman
Journal:  J Cardiovasc Transl Res       Date:  2019-02-22       Impact factor: 4.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.